Study guide
10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems
Philippine Medical Technologists Licensure Examination MTLE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Clinical Chemistry: Laboratory Operations, Instrumentation, Reagents, Quality Assurance, and Safety
1.1 Specimen Collection, Preanalytical Variables, and Interferences 1.2 Clinical Chemistry Instrumentation, Photometry, and Automation 1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics 1.4 Reagent Preparation, Laboratory Water, Glassware, Pipettes, and Centrifuges 1.5 Laboratory Safety: Chemical, Fire, Electrical, Biological, and Physical Hazards
2 Chapter 2: Clinical Chemistry: Carbohydrates, Lipids, Proteins, Non-Protein Nitrogen, and Liver Function
2.1 Glucose Homeostasis, Diagnostic Criteria for Diabetes Mellitus, and Glycemic Monitoring 2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment 2.3 Serum Proteins, Albumin, Globulins, and Serum Protein Electrophoresis Patterns 2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function 2.5 Liver Function Tests, Bilirubin Metabolism, and Jaundice
3 Chapter 3: Clinical Chemistry: Electrolytes, Blood Gases, Enzymology, Endocrinology, and Toxicology
3.1 Water Balance, Electrolytes, Osmolality, and Anion Gap Calculations 3.2 Blood Gas Analysis, Oxygenation, and Acid-Base Homeostasis 3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes 3.4 Endocrinology: Hormone Physiology and Endocrine Function Testing 3.5 Therapeutic Drug Monitoring and Clinical Toxicology
4 Chapter 4: Bacteriology: Specimen Management, Media, Staining, and Biosafety
4.1 Specimen Collection, Transport, Processing, and Microscopic Staining 4.2 Culture Media Classification, Quality Control, and Inoculation Techniques 4.3 Sterilization, Disinfection, Decontamination, and Biosafety Containment 4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms
5 Chapter 5: Diagnostic Bacteriology: Major Pathogenic Bacteria
5.1 Medically Important Gram-Positive Cocci: Staphylococci, Streptococci, and Enterococci 5.2 Medically Important Gram-Negative Bacilli: Enterobacterales and Non-Fermenters 5.3 Fastidious, Microaerophilic, and Anaerobic Bacteria 5.4 Mycobacteria, Spirochetes, Atypical Bacteria, and Public Health Microbiology
6 Chapter 6: Medical Parasitology, Mycology, and Diagnostic Virology
6.1 Stool Examination Techniques and Intestinal Nematodes 6.2 Tissue Nematodes, Filarial Worms, Cestodes, and Trematodes 6.3 Medical Protozoology: Intestinal, Urogenital, and Blood/Tissue Protozoa 6.4 Medical Mycology: Yeasts, Dermatophytes, Dimorphic Fungi, and Opportunistic Molds 6.5 Clinical Virology: Viral Structure, Specimen Handling, and Diagnostic Methods
7 Chapter 7: Hematology: Specimen Collection, Routine Parameters, Instrumentation, and Manual Methods
7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality 7.2 Automated Cell Counting Principles, Complete Blood Count Parameters, and Erythrocyte Indices 7.3 Reticulocyte Evaluation, Supravital Staining, and Erythrocyte Sedimentation Rate 7.4 Manual Cell Counts, Manual Hemoglobin Methods, and Hematology Quality Control
8 Chapter 8: Hematology: Blood Cell Morphology, Bone Marrow, and Hematologic Disorders
8.1 Normal Erythropoiesis and Erythrocyte Morphologic Abnormalities 8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies 8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations 8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders 8.5 Peripheral Blood Smear Preparation and Staining, Bone Marrow Examination, and Cytochemistry
9 Chapter 9: Hemostasis: Coagulation and Platelet Function Testing and Hemostatic Disorders
9.1 Mechanisms of Primary and Secondary Hemostasis, Fibrinolysis, and Natural Inhibitors 9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies 9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias 9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests
10 Chapter 10: Immunohematology: Blood Group Systems and Antiglobulin Testing
10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies 10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems 10.3 Antiglobulin Testing, Elution, Adsorption, and Special Antibody Procedures
11 Chapter 11: Blood Banking: Donor Operations, Component Therapy, and Adverse Reactions
11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing 11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion 11.3 Pre-Transfusion Compatibility Testing and Transfusion Reactions 11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin
12 Chapter 12: Clinical Serology and Immunology
12.1 Principles of Immunology: Antigens, Antibodies, Complement, and Immune Responses 12.2 Serologic Testing Methodologies: Agglutination, Precipitation, Flocculation, and Labeled Immunoassays 12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins 12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)
13 Chapter 13: Clinical Microscopy: Urinalysis and Renal Pathology
13.1 Renal Physiology, Urine Formation, and Physical Examination of Urine 13.2 Chemical Examination of Urine: Reagent Strip Principles, Interferences, and Confirmatory Tests 13.3 Microscopic Examination of Urine Sediment: Cells, Casts, Crystals, and Contaminants 13.4 Renal Calculi, Glomerular/Tubular/Interstitial Renal Diseases, and Urinalysis Quality Control
14 Chapter 14: Clinical Microscopy: Body Fluids, Fecal Analysis, and Gastric, Duodenal, and Respiratory Specimens
14.1 Cerebrospinal Fluid Analysis: Collection, Cell Counts, Chemistry, and Microbiology 14.2 Serous Fluids (Pleural, Pericardial, Peritoneal: Transudates vs Exudates) and Synovial Fluid Analysis 14.3 Seminal Fluid and Amniotic Fluid Analysis 14.4 Fecal Analysis: Macroscopic, Microscopic, and Chemical Examination of Stool 14.5 Gastric Fluid, Duodenal Contents, Sputum, and Bronchoalveolar Specimens
15 Chapter 15: Histopathologic Techniques and Cytotechnology
15.1 Tissue Preservation, Fixation, Decalcification, and Processing Steps 15.2 Microtomy, Sectioning Artifacts, Hematoxylin and Eosin Staining, and Special Stains 15.3 Cytotechnology: Specimen Collection, Fixation, Papanicolaou Staining, and the Bethesda System 15.4 Special Procedures: Frozen Sections, Special Embedding, Immunohistochemistry, Electron Microscopy, Autopsy, Museum Techniques, and Laboratory Records
16 Chapter 16: Medical Technology Laws, Related Laws, and Ethics
16.1 Republic Act No. 5527 (The Philippine Medical Technology Act of 1969) and Key Amendments 16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics
10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems
Key Takeaways Explain This Topic AI
The Rh blood group system is encoded on chromosome 1 by two closely linked homologous genes, RHD and RHCE, producing non-glycosylated transmembrane proteins; conversion between Fisher-Race and Wiener terminologies is essential: R0 = cDe, R1 = CDe, R2 = cDE, Rz = CDE, r = ce, r' = Cde, r'' = cdE, and ry = CdE.
Rh antigen immunogenicity follows the strict hierarchical order D > c > E > C > e; Rh antibodies are warm-reactive IgG (IgG1 and IgG3) immunoglobulins that do not bind complement and cause extravascular hemolysis and severe HDFN.
Weak D expression arises via three distinct mechanisms: genetic weak D (quantitative reduction of intact antigen sites), position effect (steric C-trans inhibition), and partial D (D mosaic with missing epitopes; partial D individuals can produce true allo-anti-D).
Weak D testing by the indirect antiglobulin test (IAT) is mandatory for all blood donors and neonates of Rh-negative mothers, but is not recommended for transfusion recipients, who are safely typed as Rh-negative to receive Rh-negative blood.
Major non-ABO systems possess distinct diagnostic signatures: Kell antigens are destroyed by sulfhydryl reagents (DTT) and anti-K suppresses fetal erythropoiesis (BFU-E); Duffy antigens (Fya, Fyb) are destroyed by enzymes and serve as Plasmodium vivax receptors (Fy(a-b-) confers malaria resistance); Kidd antibodies (Jka, Jkb) demonstrate dosage, enzyme enhancement, complement fixation, and cause severe delayed hemolytic transfusion reactions; Lewis antigens are plasma-adsorbed and transiently lost in pregnancy.
Last updated: October 2026
The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems
The Rh blood group system is the second most clinically significant system in transfusion medicine after ABO. Unlike ABO antibodies, which are naturally occurring isohemagglutinins present in all immunocompetent individuals, Rh antibodies and antibodies to other major blood group systems are immune-mediated alloantibodies produced exclusively following foreign red cell exposure via transfusion or feto-maternal hemorrhage. A detailed understanding of Rh genetics, nomenclature, weak D expression, and the distinctive serologic behaviors of non-ABO blood group systems—such as Kell, Duffy, Kidd, MNS, Lewis, P, and I—is indispensable for pre-transfusion compatibility testing, antibody identification, and the prevention of hemolytic transfusion reactions and Hemolytic Disease of the Fetus and Newborn (HDFN).
1. Molecular Genetics and Biochemistry of the Rh Blood Group System ┌─────────────────────────────────────────────────────────┐
- │ Rh System Genetics (Chromosome 1p36) │
- └────────────────────────────┬────────────────────────────┘
- │
- ┌─────────────────────────────┴─────────────────────────────┐
- ▼ ▼
- RHD Gene RHCE Gene
- (Codes for RhD protein) (Codes for RhCE protein)
- │ │
- Expresses D antigen (Rh+) • Alternative splicing produces:
- Complete deletion in Caucasian Rh- Ce, cE, ce, or CE antigens
- Inactive pseudogene in African Rh- • Both are hydrophobic 417-aa
- Point mutations in Asian Rh- transmembrane proteins with 12 loops
- Chromosomal Organization and Protein Structure
The Rh blood group antigens are encoded by two tightly linked, homologous genes located in a head-to-head orientation on chromosome 1 p 36.11 1p36.11 1 p 36.11 :
R H D RHD R HD Gene : Encodes the RhD protein , which confers Rh-positivity. In Caucasian Rh-negative individuals, the Rh-negative phenotype is caused by a complete homozygous deletion of the entire R H D RHD R HD gene ( d e l / d e l del/del d e l / d e l ). In individuals of African descent, the Rh-negative phenotype is predominantly caused by an inactive R H D RHD R HD pseudogene ( R H D ψ RHD\psi R HD ψ ) containing a 37-base pair duplication in exon 4 and a nonsense mutation that prevents functional protein expression. In Asian populations, Rh-negativity is frequently due to specific point mutations or partial R H D - R H C E RHD\text{-}RHCE R HD - R H CE hybrid genes.
R H C E RHCE R H CE Gene : Encodes the RhCE protein , which carries the C C C or c c c antigens along with the E E E or e e e antigens via alternative splicing and specific amino acid substitutions. Serine at position 103 corresponds to C C C , whereas proline corresponds to c c c ; proline at position 226 corresponds to E E E , whereas alanine corresponds to e e e .
Biochemical Properties : Unlike ABO antigens, which are carbohydrate residues attached to glycoproteins and glycolipids, Rh antigens are non-glycosylated, hydrophobic transmembrane proteins comprising 417 amino acids that traverse the erythrocyte phospholipid bilayer 12 times , with both the amino ( N H 2 NH_2 N H 2 ) and carboxy ( C O O H COOH COO H ) termini located intracellularly. Rh proteins complex with the Rh-associated glycoprotein ( R h A G RhAG R h A G ) on chromosome 6 to maintain red cell membrane skeletal integrity and facilitate ammonium transport.
The R h n u l l Rh_{null} R h n u ll Syndrome :
Caused either by the amorphic mutation (homozygous mutation/deletion of R H C E RHCE R H CE in an R H D RHD R HD -deleted background) or the regulator mutation (homozygous defect in the R H A G RHAG R H A G gene on chromosome 6, preventing membrane assembly of Rh proteins).
Erythrocytes completely lack all Rh antigens ( D , C , c , E , e D, C, c, E, e D , C , c , E , e ) and LW antigens.
Clinically, R h n u l l Rh_{null} R h n u ll red cells display structural membrane instability, presenting with stomatocytosis, spherocytosis, increased osmotic fragility , and chronic compensated extravascular hemolytic anemia. If alloimmunized, R h n u l l Rh_{null} R h n u ll patients produce an all-encompassing anti-Rh29 (anti-total Rh) , making them compatible strictly with blood from other R h n u l l Rh_{null} R h n u ll donors.
2. Rh Nomenclature Systems and Genotype Conversions
Four distinct nomenclatures describe Rh phenotypes and genotypes: Fisher-Race (CDE), Wiener ( R h - H r Rh\text{-}Hr R h - Hr ), Rosenfield numeric, and the International Society of Blood Transfusion (ISBT) numeric classification. ┌─────────────────────────────────────────────────────────────────┐
- │ Wiener to Fisher-Race Conversions │
- └───────────────────────────────┬─────────────────────────────────┘
- │
- ┌──────────────────────────────┬───────────┴───────────┬──────────────────────────────┐
- ▼ ▼ ▼ ▼
- R1 = CDe R2 = cDE R0 = cDe Rz = CDE
- (Rh-positive) (Rh-positive) (Rh-positive) (Rh-positive)
- ▲ ▲ ▲ ▲
- │ │ │ │
- r' = Cde r'' = cdE r = ce ry = CdE
- (Rh-negative) (Rh-negative) (Rh-negative) (Rh-negative)
- The Fisher-Race vs. Wiener Systems
Fisher-Race (CDE) : Hypothesized that three closely linked genetic loci encode five major antigens: D D D , C C C , c c c , E E E , and e e e . The absence of D is designated by a lowercase "d" (denoting a silent allele or deletion, not an actual antigen).
Wiener ( R h - H r Rh\text{-}Hr R h - Hr ) : Hypothesized that a single gene locus produces an agglutinogen composed of multiple antigenic "factors." Wiener shorthand symbols use uppercase R R R when the D D D antigen is present and lowercase r r r when D D D is absent:
R 1 R^1 R 1 ( C D e CDe C De ) and r ′ r' r ′ ( C d e Cde C d e ): Contain C C C (denoted by superscript 1 or single prime ′ ' ′ ).
R 2 R^2 R 2 ( c D E cDE cD E ) and r ′ ′ r'' r ′′ ( c d E cdE c d E ): Contain E E E (denoted by superscript 2 or double prime ′ ′ '' ′′ ).
R 0 R^0 R 0 ( c D e cDe cDe ) and r r r ( c e ce ce ): Contain neither C C C nor E E E (contain c c c and e e e ; basic form).
R z R^z R z ( C D E CDE C D E ) and r y r^y r y ( C d E CdE C d E ): Contain both C C C and E E E (rare alleles; denoted by z z z or y y y ).
Rosenfield and ISBT Systems
Rosenfield Numeric System : Assigns numbers based on discovery order without genetic implications: R h 1 = D Rh1 = D R h 1 = D , R h 2 = C Rh2 = C R h 2 = C , R h 3 = E Rh3 = E R h 3 = E , R h 4 = c Rh4 = c R h 4 = c , R h 5 = e Rh5 = e R h 5 = e . A minus sign indicates absence. For example, phenotype C + c + D + E − e + C+c+D+E-e+ C + c + D + E − e + is written as R h : 1 , 2 , − 3 , 4 , 5 Rh: 1, 2, -3, 4, 5 R h : 1 , 2 , − 3 , 4 , 5 .
ISBT System : Designates the Rh system as collection 004 , with each antigen given a permanent six-digit number ( 004001 = D 004001 = D 004001 = D , 004002 = C 004002 = C 004002 = C , 004003 = E 004003 = E 004003 = E , 004004 = c 004004 = c 004004 = c , 004005 = e 004005 = e 004005 = e ).
Population Frequencies and Immunogenicity
Haplotype Frequencies :
In Asian / Filipino populations: R 1 R^1 R 1 ( C D e CDe C De ) is predominant ( ≈ 70 % \approx 70\% ≈ 70% ) , followed by R 2 R^2 R 2 ( c D E cDE cD E , ≈ 20 % \approx 20\% ≈ 20% ) and R 0 R^0 R 0 ( c D e cDe cDe , ≈ 5 % \approx 5\% ≈ 5% ). The D-negative phenotype is rare in Filipinos and East Asians (well under 1% of people, compared with about 15% of Caucasians), because the r r r ( c e ce ce ) haplotype is uncommon in these populations.
In African populations: R 0 R^0 R 0 ( c D e cDe cDe ) is the most common ( ≈ 44 % \approx 44\% ≈ 44% ) , followed by r r r ( ≈ 26 % \approx 26\% ≈ 26% ) and R 1 R^1 R 1 ( ≈ 21 % \approx 21\% ≈ 21% ).
In Caucasian populations: R 1 R^1 R 1 ( C D e CDe C De , ≈ 42 % \approx 42\% ≈ 42% ) is most common, followed by r r r ( c e ce ce , ≈ 37 % \approx 37\% ≈ 37% ) and R 2 R^2 R 2 ( c D E cDE cD E , ≈ 14 % \approx 14\% ≈ 14% ).
Immunogenicity Ranking : The ability of foreign Rh antigens to stimulate antibody formation in antigen-negative recipients follows a strict hierarchy: D > c > E > C > e \mathbf{D > c > E > C > e} D > c > E > C > e
More than 50% to 85% of D-negative individuals transfused with a single unit of D-positive red cells develop anti-D alloantibodies. The c c c antigen is the second most immunogenic Rh antigen and a frequent cause of severe delayed transfusion reactions and HDFN.
- 3. Weak D Phenotypes and Transfusion Policies ┌──────────────────────────────────────────────┐
- │ Weak D Expression Mechanisms │
- └──────────────────────┬───────────────────────┘
- │
- ┌───────────────────────────────────────────────┼───────────────────────────────────────────────┐
- ▼ ▼ ▼
- ┌──────────────┐ ┌──────────────┐ ┌──────────────┐
- │ Genetic Weak │ │ Position / │ │ Partial D │
- │ D │ │ C-trans │ │ (D Mosaic) │
- └──────┬───────┘ └──────┬───────┘ └──────┬───────┘
- │ │ │
- Point mutations in trans- • Steric hindrance when • Missing D epitopes
- membrane / intracellular C allele is trans to D due to gene conversion
- Quantitative reduction (e.g., Dce / dCe) (RHD-RHCE hybrid)
- (<5,000 sites vs 30,000) • Structurally complete • Qualitative defect
- Structurally complete • Cannot form allo-anti-D • CAN FORM TRUE
- Cannot form allo-anti-D ALLO-ANTI-D!
Mechanisms of Weak D Expression
When tested at immediate-spin with commercial monoclonal anti-D, some red cells fail to agglutinate directly ( 0 0 0 ) or yield weak reactions ( < = 2 + <= 2+ <= 2 + ), but agglutinate strongly ( 3 + to 4 + 3+\text{ to }4+ 3 + to 4 + ) following 37 ∘ C 37^\circ\text{C} 3 7 ∘ C incubation and the addition of Antihuman Globulin (AHG). This weak D phenotype arises via three distinct mechanisms:
Genetic Weak D : Point mutations within the cytoplasmic or transmembrane domains of the R H D RHD R HD gene reduce the efficiency of RhD protein assembly and insertion into the red cell membrane. Antigen site density drops from a normal level of 10 , 000 – 33 , 000 10,000\text{--}33,000 10 , 000 – 33 , 000 sites/cell to fewer than 1 , 000 – 5 , 000 1,000\text{--}5,000 1 , 000 – 5 , 000 sites/cell. Crucial point : The D antigen is structurally complete (all epitopes are present); these individuals do NOT produce allo-anti-D upon exposure to normal D-positive red cells.
Position Effect / C - t r a n s C\text{-}trans C - t r an s Effect : Occurs when the C C C allele is inherited in trans position to the D D D allele on the opposite homologous chromosome (for example, genotype D c e / d C e Dce/dCe Dce / d C e , or R 0 / r ′ R^0/r' R 0 / r ′ ). The spatial conformation of the C C C protein in trans sterically hinders RhD antigen expression. The D epitopes are structurally intact, and these individuals cannot produce allo-anti-D .
Partial D (D Mosaic / D Variant) : Caused by hybrid gene formation between R H D RHD R HD and R H C E RHCE R H CE , where portions of the R H D RHD R HD gene are replaced by homologous segments of R H C E RHCE R H CE . The resulting RhD protein lacks one or more specific outer exofacial epitopes (from the complex of over 30 distinct D epitopes, epD1 through epD30). Vital Clinical Consequence : Partial D individuals CAN produce a true allo-anti-D directed against the specific missing epitopes if transfused with conventional, complete D-positive red blood cells!
Weak D Testing Protocol and Disparate Clinical Policies
Weak D testing requires incubating patient red cells with commercial anti-D reagent at 37 ∘ C 37^\circ\text{C} 3 7 ∘ C for 15 to 30 minutes, performing 3 to 4 saline washes, and adding Antihuman Globulin (AHG / Coombs reagent). ┌─────────────────────────────────────────────────────────┐
- │ Weak D Testing Clinical Policies Mandate │
- └────────────────────────────┬────────────────────────────┘
- │
- ┌──────────────────────────────┴─────────────────────────────┐
- ▼ ▼
- Blood Donors & Neonates Transfusion Recipients
• Weak D testing via IAT is MANDATORY. • Weak D testing via IAT is NOT RECOMMENDED.
• If weak D test is POSITIVE: • If immediate-spin anti-D is NEGATIVE:
Unit is labeled Rh-POSITIVE. Patient is classified as Rh-NEGATIVE.
- Rationale: Weak D red cells can stimulate • Rationale: Protects Partial D patients from
- primary anti-D alloimmunization in an receiving D-positive RBCs and developing
Rh-negative transfusion recipient. potentially fatal allo-anti-D.
Blood Donors : MANDATORY . All donor units that type negative at immediate spin with anti-D must undergo weak D testing through the AHG phase. If positive at AHG, the unit is labeled Rh-Positive because the transfused weak D red cells can easily elicit primary anti-D alloimmunization in an Rh-negative recipient.
Neonates of Rh-Negative Mothers : MANDATORY . Cord blood from infants born to Rh-negative mothers must undergo weak D testing. If the infant is weak D positive, the mother must receive Rh Immune Globulin (RhIg / RhoGAM) prophylaxis within 72 hours of delivery to prevent maternal anti-D formation.
Transfusion Recipients (Patients) : NOT RECOMMENDED / NOT REQUIRED . Patients whose red cells are negative at immediate spin are classified as Rh-Negative and must receive Rh-negative blood components. Performing weak D testing on recipients is dangerous: if a Partial D patient were tested and labeled Rh-positive, they might be transfused with D-positive blood, resulting in severe allo-anti-D immunization.
- 4. Other Major Clinically Significant Blood Group Systems ┌──────────────────────────────────────────────┐
- │ Major Non-ABO Blood Group Systems │
- └──────────────────────┬───────────────────────┘
- │
- ┌──────────────────────────┬────────────────────┴──────────────┬──────────────────────────┐
- ▼ ▼ ▼ ▼
- ┌──────────────┐ ┌──────────────┐ ┌──────────────┐ ┌──────────────┐
- │ Kell System │ │ Duffy System │ │ Kidd System │ │ MNS System │
- └──────┬───────┘ └──────┬───────┘ └──────┬───────┘ └──────┬───────┘
- │ │ │ │
- K antigen highly • Fya, Fyb destroyed • Jka, Jkb show dosage, • M, N on GPA
- immunogenic by enzymes enhanced by enzymes (destroyed by enzymes)
- Destroyed by DTT • Plasmodium vivax • Traitor antibody: drops • S, s on GPB
- Suppresses fetal receptor; Fy(a-b-) below detection; severe (enzyme resistant)
- erythropoiesis (BFU-E) confers resistance delayed HTR (DHTR) • Anti-S, s: warm IgG
- The Kell System (ISBT 006)
Antigens : Consists of high- and low-prevalence antithetical pairs: K K K (KEL1 / Kell, ~9% prevalence) and k k k (KEL2 / Cellano, 99.8% prevalence) , K p a Kp^a K p a (low) / K p b Kp^b K p b (high), and J s a Js^a J s a (low) / J s b Js^b J s b (high).
Biochemical Nature : A large single-pass transmembrane glycoprotein linked by a single disulfide bond to the Kx protein (encoded on the X chromosome).
Reagent Sensitivity : Kell antigens depend on intact disulfide bonds; they are completely destroyed by sulfhydryl reagents (such as 0.2 M 0.2\text{ M} 0.2 M dithiothreitol [DTT], 2-mercaptoethanol [2-ME], and AET), but are resistant to proteolytic enzymes (ficin and papain).
Immunogenicity & Clinical Impact : The K K K antigen is the most immunogenic non-ABO red cell antigen. Anti-K is a clinically significant warm-reactive IgG antibody. In pregnancy, maternal anti-K crosses the placenta and induces severe fetal anemia not merely by peripheral splenic hemolysis, but uniquely by binding and destroying early erythroid progenitor cells ( B F U - E BFU\text{-}E BF U - E and C F U - E CFU\text{-}E CF U - E ) , causing severe hyporegenerative fetal anemia with remarkably low reticulocyte counts.
The McLeod Phenotype : Rare X-linked condition characterized by absence of the Kx protein and severe depression of Kell antigen expression. Patients suffer from acanthocytic hemolytic anemia , elevated serum creatine kinase (CK), progressive late-onset sensorimotor neuropathy, and a strong association with X-linked Chronic Granulomatous Disease (CGD) .
The Duffy System (ISBT 008)
Antigens : The primary antithetical antigens are F y a Fy^a F y a and F y b Fy^b F y b , carried on the Duffy Antigen Receptor for Chemokines ( DARC / ACKR1 ), a seven-transmembrane glycoprotein.
Enzyme Sensitivity : Duffy antigens are completely destroyed by proteolytic enzymes (ficin, papain, and bromelin), which cleave their extracellular N-terminal domain.
Malaria Resistance : The DARC glycoprotein serves as the obligate erythrocyte receptor for merozoite invasion by the malaria parasite Plasmodium vivax (and Plasmodium knowlesi ). The F y ( a − b − ) Fy(a-b-) F y ( a − b − ) phenotype , resulting from a single nucleotide mutation in the erythroid promoter region ( G A T A - 1 GATA\text{-}1 G A T A - 1 box) that silences gene expression exclusively in erythrocytes, is present in over 68% of Black Africans , conferring near-total genetic resistance to P. vivax malaria.
Antibodies : Anti- F y a Fy^a F y a and anti- F y b Fy^b F y b are warm IgG antibodies that react optimally at the AHG phase, do not typically bind complement, and cause acute/delayed hemolytic transfusion reactions and mild HDFN.
The Kidd System (ISBT 009)
Antigens : J k a Jk^a J k a and J k b Jk^b J k b , carried on the red blood cell urea transporter protein ( UT-B / SLC14A1 ).
Dosage and Enzyme Enhancement : Kidd antigens exhibit prominent dosage (anti- J k a Jk^a J k a reacts much more strongly with homozygous J k ( a + b − ) Jk(a+b-) J k ( a + b − ) cells than with heterozygous J k ( a + b + ) Jk(a+b+) J k ( a + b + ) cells) and are significantly enhanced by proteolytic enzymes (ficin and papain).
Clinical Notoriety: Delayed Hemolytic Transfusion Reactions (DHTR) : Known in immunohematology as "the sneaky or traitor antibody." Following primary exposure, anti- J k a Jk^a J k a and anti- J k b Jk^b J k b titers rapidly decline below the analytical detection limits of routine pre-transfusion antibody screening assays. When the patient is later transfused with antigen-positive blood, an aggressive anamnestic secondary immune response produces high antibody titers within 3 to 7 days. Kidd antibodies avidly bind complement, triggering severe acute or delayed extravascular and intravascular hemolytic transfusion reactions .
J k ( a − b − ) Jk(a-b-) J k ( a − b − ) Phenotype : Rare phenotype (found predominantly in Polynesians and Finns); red blood cells lack the urea transporter and resist osmotic lysis in 2 M 2\text{ M} 2 M urea for up to 30 minutes (normal red cells lyse within 1 minute).
The MNS System (ISBT 002)
Antigens M M M and N N N : Located on the outer terminal domain of Glycophorin A (GPA) , rich in sialic acid. Destroyed completely by proteolytic enzymes (ficin and papain). Anti-M and anti-N are typically naturally occurring, cold-reactive IgM antibodies that exhibit dosage and are clinically insignificant unless they react at 37 ∘ C 37^\circ\text{C} 3 7 ∘ C or AHG.
Antigens S S S , s s s , and U U U : Located on Glycophorin B (GPB) . The U U U antigen (Universal) is a high-frequency antigen present in >99.9% of the population, located near the membrane. Anti-S, anti-s, and anti-U are warm-reactive IgG antibodies that cause severe acute and delayed HTR and HDFN.
The Lewis System (ISBT 007)
Antigens L e a Le^a L e a and L e b Le^b L e b : Lewis antigens are not synthesized by erythrocytes . Instead, soluble glycolipids synthesized by intestinal mucosal epithelial cells are secreted into plasma and passively adsorbed onto the erythrocyte membrane .
Pregnancy Loss : During pregnancy, elevated maternal plasma lipoprotein levels absorb circulating Lewis glycolipids, causing pregnant women to transiently type as L e ( a − b − ) Le(a-b-) L e ( a − b − ) . They frequently develop transient, benign Lewis antibodies that disappear following delivery.
Clinical Features : Lewis antibodies (anti- L e a Le^a L e a and anti- L e b Le^b L e b ) are naturally occurring IgM antibodies that bind complement at room temperature. They never cause HDFN because: (1) maternal IgM does not cross the placenta, and (2) fetal red cells lack Lewis antigens at birth (type as L e ( a − b − ) Le(a-b-) L e ( a − b − ) ). Lewis antibodies can be neutralized in vitro by secretor saliva or commercial Lewis substance.
The P System (ISBT 003) and Donath-Landsteiner Hemolysin
Anti- P 1 P_1 P 1 : A common, naturally occurring cold IgM antibody that can be neutralized in vitro by hydatid cyst fluid ( Echinococcus granulosus ) or pigeon egg white.
Auto-Anti-P (The Donath-Landsteiner Antibody) : Pathognomonic marker of Paroxysmal Cold Hemoglobinuria (PCH) , a severe autoimmune hemolytic anemia seen following viral infections in children or tertiary syphilis. It is a biphasic IgG autohemolysin : it binds to patient erythrocytes and fixes early complement components ( C 1 – C 4 C1\text{--}C4 C 1 – C 4 ) at reduced temperatures ( 4 ∘ C 4^\circ\text{C} 4 ∘ C ) in the peripheral capillary beds; upon rewarming to 37 ∘ C 37^\circ\text{C} 3 7 ∘ C in the central circulation, the terminal complement cascade ( C 5 b - 9 C5b\text{-}9 C 5 b - 9 ) activates, triggering sudden, massive intravascular hemolysis and dark red-brown hemoglobinuria.
The I System (ISBT 027)
Developmental Genetics : The i i i antigen represents straight, unbranched carbohydrate chains abundant on neonatal cord blood erythrocytes ("i = infant"). Over the first two years of life, the enzyme branching glycosyltransferase converts linear i i i chains into complex branched I I I antigen structures found on adult erythrocytes.
Cold Autoantibodies : High-titer auto-anti-I (IgM) is strongly associated with atypical pneumonia caused by Mycoplasma pneumoniae , causing Cold Agglutinin Disease (CAD). Conversely, auto-anti-i is associated with infectious mononucleosis caused by Epstein-Barr Virus (EBV) and Cytomegalovirus (CMV).
5. Comprehensive Blood Group System Reference Table
Blood Group System Primary Antigens Biochemical Nature Optimal Reaction Phase Typical Ig Class Ficin / Papain Enzyme Effect Complement Activation? Causes Severe HDFN? Causes HTR?
ABO A, B, H Carbohydrate on glycoprotein/lipid RT ( 20 – 24 ∘ C 20\text{--}24^\circ\text{C} 20 – 2 4 ∘ C ) / 37 ∘ C 37^\circ\text{C} 3 7 ∘ C IgM (O: IgG) Enhanced Yes (Intravascular) Yes (mild/mod) Yes (Fatal acute)
Rh D, C, c, E, e Hydrophobic transmembrane protein 37 ∘ C 37^\circ\text{C} 3 7 ∘ C / AHG IgG ( I g G 1 , I g G 3 IgG_1, IgG_3 I g G 1 , I g G 3 ) Enhanced No (Extravascular) Yes (Severe, fatal) Yes (Extravascular)
Kell K, k, K p a , K p b Kp^a, Kp^b K p a , K p b Single-pass glycoprotein (disulfide) 37 ∘ C 37^\circ\text{C} 3 7 ∘ C / AHG IgG No effect (Destroyed by DTT) Rare Yes (Suppresses BFU-E) Yes (Severe)
Duffy F y a , F y b Fy^a, Fy^b F y a , F y b Glycoprotein chemokine receptor 37 ∘ C 37^\circ\text{C} 3 7 ∘ C / AHG IgG DESTROYED Rare Yes (Mild) Yes (Acute / Delayed)
Kidd J k a , J k b Jk^a, Jk^b J k a , J k b Multipass urea transporter 37 ∘ C 37^\circ\text{C} 3 7 ∘ C / AHG IgG ENHANCED Yes (Frequent) Yes (Mild/mod) Yes (Severe Delayed / DHTR)
MNS (M, N) M, N Sialoglycoprotein (Glycophorin A) RT ( 20 – 24 ∘ C 20\text{--}24^\circ\text{C} 20 – 2 4 ∘ C ) / 4 ∘ C 4^\circ\text{C} 4 ∘ C IgM (shows dosage) DESTROYED Rare No (unless IgG at 37°C) Rare
MNS (S, s, U) S, s, U Sialoglycoprotein (Glycophorin B) 37 ∘ C 37^\circ\text{C} 3 7 ∘ C / AHG IgG S, s variable; U resistant Rare Yes (Severe) Yes (Severe)
Lewis L e a , L e b Le^a, Le^b L e a , L e b Plasma-adsorbed glycolipids RT ( 20 – 24 ∘ C 20\text{--}24^\circ\text{C} 20 – 2 4 ∘ C ) IgM Enhanced Yes NO (Not on cord cells) Occasional
P P 1 P_1 P 1 , P Glycolipid / Globoside RT / 4 ∘ C 4^\circ\text{C} 4 ∘ C (PCH: biphasic) IgM (PCH: IgG) Enhanced Yes (in PCH) No Yes (PCH: severe)
I I (adult), i (cord) Branched / linear oligosaccharides 4 ∘ C 4^\circ\text{C} 4 ∘ C / RT IgM Enhanced Yes No Rare